AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
bioAffinity Technologies, Inc.
Video analysis: BIAF
All videosNo video analysis for this stock yet. Request one from our team.
News: BIAF
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies received notice that it has regained compliance with Nasdaq's applicable listing requirements.
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16.
BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?
Shares of bioAffinity Technologies Inc. (NASDAQ:BIAF) are surging Wednesday morning as traders digest recent commercial expansion announcements alongside tight low-float trading dynamics.
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies is advancing the application of its CyPath Lung test for surveillance of lung cancer patients who have completed treatment.
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will effect a 1-for-15 reverse split of its common stock at the opening of trading on Nasdaq on August 24, 2026.
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies enters distribution agreement with AvMEDICAL to expand CyPath Lung sales reach and access to government healthcare systems.
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
JERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock.
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces closing of $4M private placement offering.
Similar companies
-
Artelo Biosciences, Inc.
ARTL
·
NASDAQ
Compare
-
GT Biopharma, Inc.
GTBP
·
NASDAQ
Compare
-
Mobile-health Network Solutions Class A Ordinary Shares
MNDR
·
NASDAQ
Compare
-
WORK Medical Technology Group Ltd. Class A
WOK
·
NASDAQ
Compare
-
Carisma Therapeutics, Inc.
CARM
·
Other OTC
Compare
-
Psyence Biomedical Ltd.
PBM
·
NASDAQ
Compare